Abstract
Background:It is unknown whether melanoma patients achieving complete response (CR) with targeted therapy can safely discontinue treatment.Methods:All patients treated with BRAF/MEK inhibitors achieving CR and ceasing treatment before progression were identified. Clinical data at treatment initiation, cessation and progression were examined.Results:A total of 12 eligible patients were identified, with median follow-up of 16 months, of whom 6 (50%) recurred at a median of 6.6 months after treatment cessation. One patient lost to follow-up until presentation with symptomatic recurrence was the only relapser to die. At relapse, the remaining five patients had an LDH <1.2 times ULN, four were ECOG 0 and one ECOG 1. Baseline characteristics and time to CR and to discontinuation did not influence the rate of relapse.Conclusions:A large proportion of patients achieving CR with BRAF/MEK inhibitors relapse after treatment cessation. The optimal treatment duration in such patients is unclear, particularly where alternative treatments are available.British Journal of Cancer advance online publication 6 October 2016; doi:10.1038/bjc.2016.321 www.bjcancer.com.
| Original language | English |
|---|---|
| Journal | British Journal of Cancer |
| DOIs | |
| Publication status | Accepted/In press - Oct 6 2016 |
Fingerprint
ASJC Scopus subject areas
- Oncology
- Cancer Research
Cite this
Cessation of targeted therapy after a complete response in BRAF-mutant advanced melanoma : a case series. / Carlino, Matteo S.; Vanella, Vito; Girgis, Christina; Giannarelli, Diana; Guminski, Alex; Festino, Lucia; Kefford, Richard F.; Menzies, Alexander M.; Long, Georgina V.; Ascierto, Paolo Antonio.
In: British Journal of Cancer, 06.10.2016.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Cessation of targeted therapy after a complete response in BRAF-mutant advanced melanoma
T2 - a case series
AU - Carlino, Matteo S.
AU - Vanella, Vito
AU - Girgis, Christina
AU - Giannarelli, Diana
AU - Guminski, Alex
AU - Festino, Lucia
AU - Kefford, Richard F.
AU - Menzies, Alexander M.
AU - Long, Georgina V.
AU - Ascierto, Paolo Antonio
PY - 2016/10/6
Y1 - 2016/10/6
N2 - Background:It is unknown whether melanoma patients achieving complete response (CR) with targeted therapy can safely discontinue treatment.Methods:All patients treated with BRAF/MEK inhibitors achieving CR and ceasing treatment before progression were identified. Clinical data at treatment initiation, cessation and progression were examined.Results:A total of 12 eligible patients were identified, with median follow-up of 16 months, of whom 6 (50%) recurred at a median of 6.6 months after treatment cessation. One patient lost to follow-up until presentation with symptomatic recurrence was the only relapser to die. At relapse, the remaining five patients had an LDH <1.2 times ULN, four were ECOG 0 and one ECOG 1. Baseline characteristics and time to CR and to discontinuation did not influence the rate of relapse.Conclusions:A large proportion of patients achieving CR with BRAF/MEK inhibitors relapse after treatment cessation. The optimal treatment duration in such patients is unclear, particularly where alternative treatments are available.British Journal of Cancer advance online publication 6 October 2016; doi:10.1038/bjc.2016.321 www.bjcancer.com.
AB - Background:It is unknown whether melanoma patients achieving complete response (CR) with targeted therapy can safely discontinue treatment.Methods:All patients treated with BRAF/MEK inhibitors achieving CR and ceasing treatment before progression were identified. Clinical data at treatment initiation, cessation and progression were examined.Results:A total of 12 eligible patients were identified, with median follow-up of 16 months, of whom 6 (50%) recurred at a median of 6.6 months after treatment cessation. One patient lost to follow-up until presentation with symptomatic recurrence was the only relapser to die. At relapse, the remaining five patients had an LDH <1.2 times ULN, four were ECOG 0 and one ECOG 1. Baseline characteristics and time to CR and to discontinuation did not influence the rate of relapse.Conclusions:A large proportion of patients achieving CR with BRAF/MEK inhibitors relapse after treatment cessation. The optimal treatment duration in such patients is unclear, particularly where alternative treatments are available.British Journal of Cancer advance online publication 6 October 2016; doi:10.1038/bjc.2016.321 www.bjcancer.com.
UR - http://www.scopus.com/inward/record.url?scp=84990177799&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84990177799&partnerID=8YFLogxK
U2 - 10.1038/bjc.2016.321
DO - 10.1038/bjc.2016.321
M3 - Article
JO - British Journal of Cancer
JF - British Journal of Cancer
SN - 0007-0920
ER -